Markets:

Overview

News

Currencies

International

Treasuries

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

48.15 -3.29 (-6.40%)

Streaming Delayed Price Updated: 11:54 AM EDT, Sep 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Why Ionis Pharmaceutical Shares Are Trading Lower Wednesday ↗

June 07, 2023

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) shares are trading lower on Wednesday after the company announced plans to offer $500 million of senior convertible notes due in 2028 in a private placement...

Via Benzinga

Analyst Expectations for Ionis Pharmaceuticals's Future ↗

June 07, 2023

Via Benzinga

Ionis Pharmaceuticals Stock Sees IBD RS Rating Climb To 79 ↗

May 24, 2023

The Relative Strength Rating for Ionis Pharmaceuticals stock moved into a new percentile Wednesday, as it got a lift from 65 to 79.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023 ↗

May 04, 2023

Via Benzinga

Recap: Ionis Pharmaceuticals Q1 Earnings ↗

May 03, 2023

Via Benzinga

Ionis Pharmaceuticals's Earnings Outlook ↗

May 02, 2023

Via Benzinga

Analyst Expectations for Ionis Pharmaceuticals's Future ↗

April 11, 2023

Via Benzinga

Analyst Ratings for Ionis Pharmaceuticals ↗

March 21, 2023

Via Benzinga

Ionis Pharmaceuticals's Earnings Outlook ↗

February 21, 2023

Via Benzinga

Biogen's Amyotrophic Lateral Sclerosis Drug Scores Conditional Approval From FDA ↗

April 26, 2023

The FDA approved Biogen Inc's (NASDAQ:

Via Benzinga

What's Going On With Biogen Stock Tuesday? ↗

April 25, 2023

Biogen Inc (NASDAQ: BIIB) shares are trading lower Tuesday. The company reported first-quarter results before the bell and the FDA approved its ALS therapy Tuesday afternoon.

Via Benzinga

Biogen Announces Additional Cost Cutting Initiatives, Chops Certain Stroke, Gene Therapy Programs ↗

April 25, 2023

Via Benzinga

3 Biotech Stocks to Sell Before They’re 6 Feet Under ↗

April 24, 2023

Biotech stocks with no earnings, no cash, and no path to profit will have no chance at survival. Here's three such biotech stocks to avoid.

Via InvestorPlace

AstraZeneca, Ionis Unveil Complete Phase 3 Data For ATTR Candidate, Says Drug Halts Disease Progression ↗

April 24, 2023

Via Benzinga

Could This Rare-Disease Drug Candidate Become a Blockbuster? ↗

April 19, 2023

This drug candidate could be a great treatment option for patients with a potentially deadly disease.

Via The Motley Fool

Analyst Expectations for Ionis Pharmaceuticals's Future ↗

January 19, 2023

Via Benzinga

The Latest Analyst Ratings for Ionis Pharmaceuticals ↗

December 21, 2022

Via Benzinga

Ionis Pharmaceuticals Earnings Perspective: Return On Capital Employed ↗

December 13, 2022

Via Benzinga

Analyst Upgrades Arrowhead Pharma Citing 'Attractive Risk/Reward' ↗

April 12, 2023

SVB Securities upgraded Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) to Outperform from Market Perform on attractive risk-reward following shares' underperformance relative to larger cap oligo therapy...

Via Benzinga

AstraZeneca-Ionis Partnered Rare Disease Drug Data Shows Sustained Benefit; Drug Under FDA Review ↗

March 27, 2023

Via Benzinga

Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement ↗

March 23, 2023

The companies are focusing on a small population of ALS patients with a genetic mutation.

Via Investor's Business Daily

FDA Adcomm Says Benefit-Risk Profile Favor Biogen's Tofersen For Inherited Neuro Disorder ↗

March 23, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023 ↗

March 21, 2023

Via Benzinga

Biogen Triumphs In Legal Battle Regarding Tecfidera, Delaying EU Generic Erosion For Another Year ↗

March 16, 2023

Via Benzinga

Analyst Says Ionis' Additional Hereditary Angioedema Study Data Supports 'Highly Competitive Profile' ↗

February 21, 2023

Via Benzinga

Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric ↗

February 02, 2023

The company that remains still has a large pipeline of non-migraine assets.

Via Investor's Business Daily

Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness

January 09, 2023

From Royalty Pharma plc

Via GlobeNewswire

Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies

January 04, 2023

From Biogen Inc.

Via GlobeNewswire

Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm ↗

November 16, 2022

Neurodegenerative disorders could mean big bucks for some biotechs.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For December 21, 2022 ↗

December 21, 2022

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.